Reply to: "Improved basic performance of iTACT-HBcrAg assay" and "Using a commercial diagnostic assay requires compliance with the manufacturer's recommendations"

J Hepatol. 2023 Sep;79(3):e136-e137. doi: 10.1016/j.jhep.2023.05.047. Epub 2023 Jun 29.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment